欧洲临床实践中药物不良反应报告里生物制剂的标识可辨识性
本研究评估了2011年至2016年6月欧洲临床实践中收到的10类相似或相关生物制剂在不良反应报告中可追溯至生产商的比例。结果显示96.7%的疑似生物制剂有充分标识,但批号可追溯性仅20.5%,提示生产商层面识别稳健而批号追溯仍需改进。
要点
- 96.7%的疑似生物制剂报告可识别至生产商,不同类别范围89.5%至99.8%。
- 生物类似药引入后,相关类别生物制剂的产品可识别性持续保持高位。
- 仅20.5%的疑似生物制剂报告确保批号可追溯,需进一步加强。
核心结论
- 欧洲不良反应报告系统对生物制剂识别至生产商层面是稳健的,可支持及时检测产品特异性安全信号。
- 批号可追溯性仅20.5%,需进一步改进。
研究设计与样本
- 研究分析了2011年至2016年6月欧洲临床实践中收到的10类相似或相关生物制剂的不良反应报告。
主要发现
- 96.7%的疑似生物制剂报告了充分标识,范围从非格司亭的89.5%到干扰素β-1a的99.8%。
- 在随访期间引入生物类似药的类别中,产品可识别性随时间持续保持高位。
- 总体批号可追溯性仅20.5%的疑似生物制剂得到保证。
临床怎么用
- 临床报告生物制剂不良反应时应提供充分标识以识别至生产商,并尽量记录批号以支持追溯。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biologicals are established treatment options that require pharmacovigilance adapted to their specific nature, including the need for products to be identifiable up to the specific manufacturer in reports of adverse drug reactions (ADRs). This study explored the identifiability of 10 classes of similar and related biologicals up to the level of the manufacturer in ADR reports received from European clinical practice between 2011 and June 2016. Adequate identifiers were reported for 96.7% of the suspected biologicals, ranging from 89.5% for filgrastim to 99.8% for interferon beta-1a. The product identifiability remained consistently high over time for classes of biologicals for which biosimilars were introduced during follow-up. The overall batch traceability was, however, only ensured for 20.5% of the suspected biologicals and needs further improvement. This study shows that the European system for identification of ADRs to the level of the manufacturer is robust, allowing for the timely detection of potential product-specific safety signals for biologicals.
引用
- Vermeer NS, Giezen TJ, Zastavnik S, et al. Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice. Clin Pharmacol Ther. 2019. PMID: 30460997. doi:10.1002/cpt.1310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。